Simtra BioPharma Solutions, a global CDMO specializing in injectable medicines, has purchased a 65-acre property with more than 300,000 sq.-ft. of available space for expansion under-roof near its existing manufacturing facility in Bloomington, IN.

The addition of this site provides Simtra with significant flexibility to rapidly expand its manufacturing footprint in the U.S. to respond to growing capacity demands from both new and existing customers.

“This purchase gives us the foundation to grow with purpose, building the advanced injectable capacity our customers need while strengthening our presence in North America,” said Franco Negron, CEO, Simtra BioPharma Solutions. “It reflects our long-term commitment to delivering vital injectable products and helping our customers navigate complex global supply chains.”

Simtra is evaluating a project to design and install manufacturing lines at the site, including the company’s first U.S.-based commercial-scale capacity for oncology-focused injectable drug products. The facility would run isolator-based vial and prefilled syringe filling lines.

This purchase from Cook Group complements other previously announced investments in the company’s growth, including the $250 million construction project currently underway at Simtra’s existing Bloomington manufacturing site, and the recently completed $100+ million new production building and $14 million conjugation and purification suite being built in Halle/Westfalen, Germany.